Description:
<jats:p>In the Phase 3 SURPASS studies of adults with T2D, the GIP/GLP-1 receptor agonist tirzepatide (TZP) provided clinically meaningful reductions in HbA1c levels and body weight. In this post-hoc analysis of TZP-treated participants in SURPASS 1-5 studies, we assessed whether those shifting to a lower BMI category would improve in cardiometabolic measures such as HbA1c, waist circumference (WC), systolic blood pressure (SBP), and lipid profiles. Changes in BMI category (&lt;25 kg/m², 25- &lt;30 kg/m², 30- &lt;35 kg/m², 35- &lt;40 kg/m², ≥40 kg/m²) from baseline to endpoint were assessed by study (N=3559), regardless of dose. BMI category shifts were grouped into “Improved” (shift to a lower BMI category, by at least one category), or “Stable/Worse” (no change/shift to a higher BMI category). At baseline, participants averaged 58 years, 93.36 kg, 53.6% were male, and 79.5% were white. While improvements in cardiometabolic measures were observed in both subsets of participants, numerically greater improvements in HbA1c, WC, SBP and lipid profile were observed for the 59% who improved their BMI category (Table 1). In the SURPASS studies, shifting to a lower and improved BMI category compared to a stable or worse BMI category was associated with greater improvement in cardiometabolic measures including HbA1c, WC, SBP, and lipid profile.</jats:p>
<jats:p />
<jats:sec>
<jats:title>Disclosure</jats:title>
<jats:p>R.Wiese: Employee; Eli Lilly and Company. A.Dib: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. C.Nicolay: Employee; Eli Lilly and Company. S.Allen: None. C.Lee: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Funding</jats:title>
<jats:p>Eli Lilly and Company</jats:p>
</jats:sec>